Relmada Therapeutics has appointed Bipin Dalmia as Chief Business Officer. Dalmia brings nearly three decades of biopharmaceutical leadership, including deep expertise in non-muscle invasive bladder cancer, or NMIBC, and experience with the first FDA-approved intravesical gene therapy for bladder cancer patients. He will lead corporate strategy, commercial planning, and business development, reporting to CEO Sergio Traversa. The appointment comes as Relmada advances NDV-01, its novel sustained-release intravesical therapy for NMIBC, toward late-stage development. Dalmia previously served as Senior Vice President, Global Head of Portfolio Strategy and Business Development at Ferring Pharmaceuticals, where he led the U.S. launch of ADSTILADRIN and completed more than 20 strategic transactions.
Relmada Therapeutics IncAppointment of experienced CBO to lead strategy and business development as NDV-01 advances toward late-stage development.